KDM6A and chronic myelomonocytic leukemia: UTX deficiency was associated with the aggregation of reactive oxygen species, reduced DNA damage repair, and aging in HSPCs.432 Regarding hematologic malignancies, UTX mutations were found in 8% of CMML patients.74UTX has been demonstrated to be a tumor suppressor that represses myeloid leukemogenesis and preserves drug sensitivity in MDS, AML, APL, and even T-ALL.433–437 However, studies also discovered that UTX served as a pro-oncogenic cofactor indispensable to leukemia development in TAL1-positive T-ALL, and UTX inhibition significantly impeded TAL1-positive leukemia.438